Skip to main content
Equibles

ARGX · Argenx SE

Track ARGX — free

Use ARGX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ARGX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$947.39 -11.52 (-1.20%)
Rebalance outlook locked
Market Cap
$60.40B
Shares
62.56M
Volume · Sep 30 243.75K Avg daily vol (3M) 283.45K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$958.91 Open$970.08 Day$952.27–970.27 52W close$663.93–1,058.90 Avg vol 30d258K Short int1.3M · 2.1% float · 6.3d Short vol63% Last earningsDec 31, 2025 DataJan 2020–Sep 2026

Up next

Q4 2025 earnings call transcript
call held Dec 31, 2025

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+88.6%
Year over year
Operating margin
24.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.8%
Year over year · more shares
Price change (1Y)
+35.0%
Trailing year
Short interest
2.1%
Latest settlement · 6.3 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Neutral Momentum Strong Sentiment Neutral Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 16.3 · calm Equity put/call 0.53
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +13%
above
Price vs 50-day avg +0%
above
RSI (14) 45
neutral
MACD trend Negative
52-week position 75%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Strong
1-month return −7%
trailing
6-month return +20%
trailing
YTD return +14%
this year
Relative strength +8%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $955 › 200d $851 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +84 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.10% of float · ▲ +4.3% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
511 holders — near 3-yr high, broad support
Squeeze score 58
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 35%
annualized · 1-yr
Max drawdown −29%
past year
ATR 2.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 2
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+13% Bullish
Price vs 50-day avg
+0% Bullish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
75% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $955 › 200d $851 — 50d above 200d
Institutional flow Accumulating
+7% holders QoQ · +84 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.10% of float · ▲ +4.3% MoM · 6.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
511 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $664 Now $959 · 75% Range high $1,059
vs 200-day avg +13% vs 50-day avg +0%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ARGX
Argenx SE
this stock
$60.40B +14.0% — — 2.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +15.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -1.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +553.0% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
511
% held
45.7%
Net QoQ
-670.8K sh
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
371
View
Short & Settlement
Short Interest Rising
Shares short
1.3M
Days to cover
6.3d
Change
+53.8K sh
View
Short Volume
Short vol %
63%
As of
Sep 30, 2026
Short Total
View
Fails to Deliver
FTD shares
21
Value
$21.0K
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
53.7%
Week of
Aug 24, 2026
Off-exch Lit
View
Smart Money
Congressional Trades Sell
Member
Daniel Goldman
Amount
$1.0K–$15.0K
Traded
Jul 10, 2023
View
Financials
Financials
Net income (FY)
EUR -163.0M
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 29, 2026
This year
26
View
Earnings & Events
Earnings Calls
Last call
Sep 14, 2026
View

Performance

5D 20D 120D MTD YTD
ARGX +1.4% -6.8% +19.8% -7.1% +14.0%
SPY -0.7% +0.1% +12.2% -0.6% +11.8%
vs SPY +2.1% -6.9% +7.6% -6.5% +2.2%
Key facts CIK 1697862 CUSIP 04016X101 13F (30d) 11 filings 11 filers Visit website Investor relations